Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01413503 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01413503 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 50 participants.
The verdict
NCT01413503, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is an ongoing prospective Phase II clinical trial evaluating the efficacy of 131I-MIBG for the treatment of patients with metastatic or unresectable pheochromocytoma and related tumors.
Interventions
- RADIATION 131I-MIBG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1991-05 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01413503
The ClinicalTrials.gov registry entry for NCT01413503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 131I-MIBG is the first listed.
NCT01413503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01413503 about?
NCT01413503 is a clinical study titled "A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors". This is an ongoing prospective Phase II clinical trial evaluating the efficacy of 131I-MIBG for the treatment of patients with metastatic or unresectable pheochromocytoma and related tumors.
What is the current status of trial NCT01413503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1991-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT01413503?
The interventions under investigation include: 131I-MIBG (RADIATION).
Who is sponsoring clinical trial NCT01413503?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.